Overview

This trial is active, not recruiting.

Condition extranodal nk/t-cell lymphoma, nasal type
Treatments high dose of methotrexate, gemcitabine, pegaspargase, dexamethasone
Phase phase 2
Sponsor Sun Yat-sen University
Collaborator Eli Lilly and Company
Start date November 2013
End date December 2016
Trial size 30 participants
Trial identifier NCT01991158, B2013-030-01

Summary

The purpose of this study is to evaluate the efficacy and safety of High dose of Methotrexate combined with gemcitabine, pegaspargase and dexamethasone (GAD-M regimen) as first-line treatment in patients with de novo extranodal NK/T cell lymphoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
GAD-M regimen means High dose of methotrexate combined with gemcitabine, pegaspargase and dexamethasone
high dose of methotrexate
Methotrexate 3.0g/Kg, intravenous drip D1
gemcitabine
Gemcitabine 1g/m2 intravenous drip D1,D8
pegaspargase
Pegaspargase 2500U/m2 intramuscular injection (IM) D1
dexamethasone
Dexamethasone 20mg/d intravenous drip D1, po D2-3

Primary Outcomes

Measure
Overall Response Rate (ORR)
time frame: every 6 weeks, up to completion of treatment (approximately 6 months)

Secondary Outcomes

Measure
Progress Free Survival (PFS)
time frame: up to end of follow-up-phase (approximately 5 years)
Overall Survival (OS)
time frame: up to the date of death (approximately 5 years)

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - Histologic diagnosis of NK/T Cell Lymphoma; - Age:18-80 years; - Weight:Male:67±20Kg(47-87Kg),Female:55±20Kg(35-75Kg) - Eastern Cooperative Oncology Group (ECOG) status 0-3, Estimated survival time > 3 months; - No history of other malignancies; No other current tumors; - Normal haematological, liver and renal function (WBC count≥3.5×109/L, Hemoglobin≥100g/L, platelet count≥90×109/L, bilirubin<1.5×ULN, Alanine transaminase (ALT) and Aspartate Aminotransferase (AST)<2.5×ULN, serum creatinine<1.5×ULN), normal coagulation function and cardiac function; - Clinical staging I-IV; - No previous treatments including chemotherapy, radiotherapy, targeted therapy or stem cell transplantation; - Appreciable and measurable lesions, clinical assessment >2cm,CT or MRI >1.5cm; - No other serious diseases which conflict with the treatment in the present trial; - No concurrent treatments that conflict with the treatments in the present trial(including steroid drugs); - Voluntary participation and signed the informed consent. Exclusion Criteria: - The patients had the conditions below: clinically significant ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), symptomatic coronary artery heart disease requiring medication; - The patients suffered from organ transplant - The patients participated in other clinical trials within the 30 days before enrollment or who are participating in other clinical studies; - The patients with active bleeding or new thrombotic disease, who are taking anticoagulant drugs or with a history of bleeding tendencies,who with active infection; - The patients suffered before surgery less than four weeks, or after less than six weeks; - The patients with abnormal liver function (total bilirubin> 1.5 times the normal value, ALT / AST> 2.5 times normal), abnormal renal function (serum creatinine> 1.5 times normal), blood abnormalities (absolute neutrophil count <1.5 × 109 / L, platelets <80 × 109 / L, hemoglobin <90g /L) ; - The patients with mentally ill / unable to obtain informed consent; - The patients with drug addiction, alcohol abuse which affects the long-term evaluation of test results; - The patients in pregnancy, lactation and women of childbearing age who do not want to take contraceptive measures subjects; - Clinical and laboratory support brain metastases; - The patients with a history of allergy or adverse reaction(s) to test drug; - The patients not suitable to participate in the investigator judged by researchers.

Additional Information

Official title An Open, Single-center, Phase II Clinical Trial for Treatment of Untreated Extranodal NK/T Cell Lymphoma With High Dose of Methotrexate in Combination With Gemcitabine, Pegaspargase and Dexamethasone (GAD-M Regimen)
Principal investigator Wenqi Jiang, MD
Description Studies have shown that effects of P glycoprotein mediated chemotherapy resistance reduce the therapeutic efficacy of anthracycline-based chemotherapy of NK/T cell lymphoma, and agents like pegaspargase and large doses of Methotrexate is not affected by the P glycoprotein. A number of reports suggest that gemcitabine combined with other chemotherapy drugs has good application prospect in the treatment of lymphomas. Dexamethasone is used in combination with other agents for the treatment of lymphomas which may be implicated in the development or growth of some cancers. So we explored to evaluate the efficacy and safety of High dose of methotrexate combined with gemcitabine, pegaspargase and dexamethasone (GAD-M regimen) as first-line treatment in patients with untreated extranodal NK/T cell lymphoma.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Sun Yat-sen University.